Charles Moore,  —

Charles is a force to be reckoned with in the world of print and new media. From an interview with him in LowEndMac: ”His articles, features, and commentaries have appeared in more than 40 magazines, newspapers and websites in Canada, the US, the UK, and Australia. . . a columnist for The Halifax Daily News and the Saint John Telegraph Journal, Atlantic Fisherman, and news editor and columnist for, a columnist and contributing editor for MacOpinion and PBCentral, as well as writing for Low End Mac.” Charles serves as the Senior Section Editor for the Science and Research section of BioNews Texas and contributes science-related articles on a daily basis.

Articles by Charles Moore

Jiffy Lube, MDA Launch 6th Annual MUSCLE UP! Campaign

Jiffy Lube and the Muscular Dystrophy Association (MDA) are teaming up again this summer for the 6th annual MUSCLE UP! campaign. Each August for the past five years, Jiffy Lube has campaigned in support of MDA-funded muscular dystrophy and related neuromuscular disease research and programs to help…

CureDuchenne Ventures Invests in TRiNDS to Provide Clinical Trial Expertise

CureDuchenne Ventures is investing in Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS), a new specialized contract research organization. TRiNDS is hived off from the Cooperative International Neuromuscular Research Group (CINRG), an academic consortium that studies causes, pathogenesis and clinical outcomes of neuromuscular disorders, and conducts well-controlled clinical studies…

Catabasis Previews MoveDMD Phase 2 Trial Results at Investor Day

At Catabasis Pharmaceuticals’ first Investor Day earlier this month, the company provided an in-depth review of its strategy and development pipeline of product candidates for treating rare diseases, including the Duchenne muscular dystrophy drug edasalonexent (CAT-1004). Guest speakers included Craig McDonald, MD, director of the NeuroNEXT Program at…

Forums CTA